" class="no-js "lang="en-US"> APATICS Appoints New CEO - Medtech Alert
Monday, February 26, 2024

APATICS Appoints New CEO

APATICS, Inc. announced that co-founder, CEO and Chairman of APATICS Inc., Dimitri Arges, has stepped down to pursue other interests. Clay Wilemon has been appointed as CEO effective immediately.

Mr. Arges played an instrumental role in shaping product strategy, development and commercial readiness at APATICS over the last five years. This work included establishing important business and innovation partnerships for the Company.  Mr. Arges states, “I am thrilled to see APATICS’ patented technology enter commercialization and address two of the biggest problems in the United States healthcare system: 1) Fraud, Waste and Abuse (FWA) and 2) issues with provider data accuracy, integrity and management. FWA is a $700 billion dollar drain on the healthcare system that is preventable with APATICS’ patented AI solutions that address FWA from both a claims and provider level in real-time. Provider data management and credentialing is a $5 billion dollar cost to the health system that can be dramatically reduced with APATICS’ automated, continuous-credentialing capability.”

Mr. Wilemon is an investor in APATICS and has served as President and Chief Commercial Officer since August 2021.  Mr. Wilemon brings a wealth of healthcare industry experience and commercialization success to the company. He has helped to define and launch over 500 new healthcare brands in the United States and around the world.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more